For research use only. Not for therapeutic Use.
BM212（Cat No.:I001770）is a selective small molecule inhibitor of the IκB kinase (IKK) complex, specifically targeting IKKβ. It plays a crucial role in modulating the NF-κB signaling pathway, which is involved in inflammatory responses, immune regulation, and cell survival. By inhibiting IKKβ, BM212 effectively suppresses the activation of NF-κB and downstream pro-inflammatory cytokine production. This compound holds potential for therapeutic applications in diseases characterized by excessive inflammation, such as autoimmune disorders, cancer, and chronic inflammatory diseases. Its targeted mechanism makes BM212 a valuable tool for research and drug development in immunology.
| Catalog Number | I001770 |
| CAS Number | 146204-42-4 |
| Molecular Formula | C23H25Cl2N3 |
| Purity | ≥95% |
| Target | Bacterial |
| Solubility | 10 mM in DMSO |
| Storage | -20°C |
| IUPAC Name | 1-[[1,5-bis(4-chlorophenyl)-2-methylpyrrol-3-yl]methyl]-4-methylpiperazine |
| InChI | InChI=1S/C23H25Cl2N3/c1-17-19(16-27-13-11-26(2)12-14-27)15-23(18-3-5-20(24)6-4-18)28(17)22-9-7-21(25)8-10-22/h3-10,15H,11-14,16H2,1-2H3 |
| InChIKey | YWZIODCWLMCMMW-UHFFFAOYSA-N |
| SMILES | CC1=C(C=C(N1C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)CN4CCN(CC4)C |
| Reference | </br>1:Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N/’-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercular Agents Effective against Multidrug-Resistant Mycobacteria. Bhakta S, Scalacci N, Maitra A, Brown AK, Dasugari S, Evangelopoulos D, McHugh TD, Mortazavi PN, Twist A, Petricci E, Manetti F, Castagnolo D.J Med Chem. 2016 Mar 24;59(6):2780-93. doi: 10.1021/acs.jmedchem.6b00031. Epub 2016 Mar 8. PMID: 26907951 </br>2:Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. Poce G, Bates RH, Alfonso S, Cocozza M, Porretta GC, Ballell L, Rullas J, Ortega F, De Logu A, Agus E, La Rosa V, Pasca MR, De Rossi E, Wae B, Franzblau SG, Manetti F, Botta M, Biava M.PLoS One. 2013;8(2):e56980. doi: 10.1371/journal.pone.0056980. Epub 2013 Feb 21. PMID: 23437287 Free PMC Article</br>3:MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR, Biava M, Raju RM, Porretta GC, Alfonso S, Battilocchio C, Javid B, Sorrentino F, Ioerger TR, Sacchettini JC, Manetti F, Botta M, De Logu A, Rubin EJ, De Rossi E.Antimicrob Agents Chemother. 2012 Jan;56(1):324-31. doi: 10.1128/AAC.05270-11. Epub 2011 Oct 24. PMID: 22024828 Free PMC Article</br>4:New derivatives of BM212: A class of antimycobacterial compounds based on the pyrrole ring as a scaffold. Biava M, Porretta GC, Manetti F.Mini Rev Med Chem. 2007 Jan;7(1):65-78. Review. PMID: 17266639 </br>5:Antimycobacterial agents. Novel diarylpyrrole derivatives of BM212 endowed with high activity toward Mycobacterium tuberculosis and low cytotoxicity. Biava M, Porretta GC, Poce G, Supino S, Deidda D, Pompei R, Molicotti P, Manetti F, Botta M.J Med Chem. 2006 Aug 10;49(16):4946-52. PMID: 16884306 </br>6:Antimycobacterial compounds. New pyrrole derivatives of BM212. Biava M, Porretta GC, Deidda D, Pompei R, Tafi A, Manetti F.Bioorg Med Chem. 2004 Mar 15;12(6):1453-8. PMID: 15018918 </br>7:New pyrrole derivatives as antimycobacterial agents analogs of BM212. Biava M, Fioravanti R, Porretta GC, Deidda D, Maullu C, Pompei R.Bioorg Med Chem Lett. 1999 Oct 18;9(20):2983-8. PMID: 10571160 </br>8:Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Deidda D, Lampis G, Fioravanti R, Biava M, Porretta GC, Zanetti S, Pompei R.Antimicrob Agents Chemother. 1998 Nov;42(11):3035-7. PMID: 9797251 Free PMC Article |
